menu

NEWS

5AM VENTURES APPOINTS YUJIRO HATA AS EXECUTIVE-IN RESIDENCE

 

Menlo Park, CA, August 11, 2015 – 5AM Venture Management LLC (5AM), of Menlo Park, CA and Boston, MA, is pleased to announce the addition of Yujiro Hata as an Executive-in-Residence of 5AM. Mr. Hata will also serve as Chief Executive Officer of IDEAYA Biosciences, a 5AM incubated oncology company.

“We are delighted to welcome Mr. Hata, and look forward to partnering with him to build IDEAYA Biosciences.” said Dr. John Diekman, Managing Partner of 5AM Ventures. “5AM is committed to bringing together breakthrough science with talented entrepreneurs to form the next generation of biotechnology companies. We are excited to continue to implement this model at 5AM, leveraging our investment and operating capabilities.”

Mr. Hata is an entrepreneur with 20 years of operating experience building biotechnology companies that have brought to market innovative therapies for patients with cancer and other unmet medical needs. From 2014 to August 2015, Yujiro served as Chief Operating Officer at immuno-oncology companies Flexus Biosciences and spinout FLX Bio, which he joined as a startup and led through its acquisition by Bristol-Myers Squibb in April 2015, where he oversaw all business operations, corporate strategy, and M&A and licensing. From 2010 through its acquisition in October 2013 by Amgen, Mr. Hata was Vice President, Corporate Development & Strategy at Onyx Pharmaceuticals (NASDAQ: ONXX), where he held various leadership roles, including Head of Strategy and Strategic Asset Management, and Head of M&A and Licensing. From 2002 to 2010, Mr. Hata served as Vice President, Senior Vice President, and Chief Business Officer at Enanta Pharmaceuticals (NASDAQ: ENTA), which he joined as a startup and helped build into a public company that received Breakthrough Therapy Designation and FDA approval for Viekira Pak. He previously served in roles spanning business and R&D at McKinsey & Company, ImClone, and Columbia Medical School.

Mr. Hata obtained his MBA at Wharton, as a Henry J Kaiser recipient, and completed undergraduate studies in chemistry at Oxford University and Colorado College. He serves on the Board of Directors at Xencor (NASDAQ: XNCR), and on the Board of Visitors of the Moores Cancer Center, at the University of California, San Diego.

 

About 5AM Ventures

Founded in 2002, 5AM Ventures actively invests in next-generation life science companies. The firm is currently investing 5AM Ventures IV, L.P., a $250 million venture capital fund which closed in 2013. With over $685 million under management, 5AM has invested in over 50 early-stage companies and its successful realizations include DVS Sciences (sold to Fluidigm), Envoy Therapeutics (sold to Takeda), Flexion Therapeutics (Nasdaq: FLXN), Ikaria (sold to Mallinckrodt), Ilypsa (sold to Amgen), Incline Therapeutics (sold to The Medicines Company), Marcadia (sold to Roche), Pearl Therapeutics (sold to AstraZeneca), and Relypsa (Nasdaq: RLYP). For more information, please visit www.5amventures.com.

Contact:
5AM Venture Management LLC
Andy Schwab, Managing Partner
Phone: +1-650-233-8604
Email: [email protected]